This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antibody Therapy Market

Antibody Therapy Over Chemotherapy! Patients move toward Proteins instead of Chemicals for the Therapy

Antibody Therapy Market by Type, End User & Region | Forecast 2023 to 2033

Antibody Therapy Market Outlook

The antibody therapy market is set to thrive at a steady CAGR of 13.4% during the forecast period. The market holds a share of US$ 235 billion in 2023 while it is anticipated to cross a value of US$ 824.0 billion by 2033.

The research report on the antibody therapy market explains that progressive healthcare efforts, along with the higher government spending on research and development programs, have helped the antibody therapy market expand. Patients suffering from cell-based diseases along with cancer have started opting for the non-chemical, protein-based model that monoclonal antibody therapy provides.

The research and development programs that provide substantial data on higher effectiveness and lower side effects are likely to increase the operability of monoclonal antibody therapy, flourishing the sales of antibody therapies. Furthermore, the expansion of cancer-centric hospitals flourishes the demand for antibody therapy solutions.

The higher FDA approvals of advanced antibody therapy for Covid-19 cases boomed the market growth during the peak of the pandemic. Hence, the market flourished on a much higher CAGR of 18.2% between 2017 and 2022.

The antibody therapy market outlook states that tumor cell resistance to immunotherapy and chemotherapy side effects are also pushing the demand for an alternative. The monoclonal antibodies have become that one alternative with shorter by higher effectiveness.

Thus, the segment becomes the dominant one in the market space. Over the forecast period, the worldwide antibodies market is driven by rising cancer and some other chronic disease prevalence, increasing regulatory approvals and the launch of medicines, and increasing research partnerships for creating a vigorous therapeutic pipeline.

Attributes

Details

Antibody Therapy Market CAGR (2023 to 2033)

13.4%

Antibody Therapy Market Size (2023)

US$ 235.0 billion

Antibody Therapy Market Size (2033)

US$ 824.0 billion

Customize this Report

Let us know your requirement to get
100% FREE customization

How is the Future Outlook (2023 to 2033) for Antibody Therapy Market in Comparison to the Historical Pattern (2017 to 2022)? 

Short-term Growth: From 2017 to 2022, the global Antibody Therapy market registered a comparatively higher CAGR of 12.1%. The rising prevalence of cancer and its high mortality rate had increased the need for effective and tailored medicines, such as antibody therapy. Antibody-based treatments have evolved technologically by targeting tumor antigens and increasing immune cells' anti-tumor capabilities. Though, the major factor for it experiencing the excessive growth during this period was its experiments against the COVID-19 spread and its usage.

Mid-term Growth: The antibody therapy market is predicted to develop due to rapid product advancement and technologies for cancer treatment. Antibody therapy is a focused, therapeutic intervention that involves using a concentrated or monoclonal antibody to treat diseases such as cancer, infectious disorders, autoimmune diseases, and other The market is likely to grow steadily between 2023 and 2028.

Long-term Growth: Antibodies bind to a specific antigen, which activates or inhibits a series of biological responses, including cancer development inhibition, immune system activation, and many more. During the forecast period, the market for antibody therapy is expected to rise at a steady pace. The Antibody Therapy market is anticipated to thrive at a CAGR of 13.4% between 2023 and 2033.

What Contributes to the Growth of the Antibody Therapy Market?

Owing to the strong demand for antibody therapy, the government and key market companies have greatly expanded research and development spending. As a result, the operation moves to a larger size.

Strong market growth is projected due to government backing for the launch of new treatments. The rising frequency of cancer and other chronic diseases is one of the primary factors driving the global monoclonal antibodies market.

Additionally, increasing regulatory approvals and the debut of new medicines are complementing market growth. The global cancer risk is rapidly increasing, and more secure clinical treatment is being sought over traditional methods.

Monoclonal antibodies may provide advantages, such as recognizing and eliminating a typical cell directly, suppressing cancer cell development, and delivering radioactive particles or chemo medicines to specific cells, reducing the danger of drug side effects while enhancing immune system function.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are Obstacles for the Antibody Therapy Market Players?

The results of screening and clinical tests are influenced by antibody variation. The development process is a lengthy and challenging task. The technology necessitates huge bioreactors and filtration systems for antibody synthesis, which hinders the worldwide antibody treatment industry.

The market's expansion may be hampered by high costs and tight regulatory requirements that result in a protracted approval process.

What are the Trends followed by the Antibody Therapy Market?

Rising governmental spending in cancer research and technology development may open up new potential for the worldwide antibody therapy market to expand.

The healthcare industry is growing at a breakneck speed. The antibody therapy market is experiencing rapid growth due to these advances. On the other hand, more medication market development may be able to help. Antibody treatment alternatives are exploding. In the forecast period, this may have an impact on the overall demand for antibody medication therapy. It can also lead to a plethora of replacements.

The FDA approved Amgen's Repatha (evolocumab) in September 2021 to treat heterozygous familial hypercholesterolemia (HeFH) patients aged 10 and up. Patients suffering from HeFH benefit from this approval. Seagen Inc. and Astellas Pharma Inc. also announced FDA clearance of PADCEV in the United States in September 2021. PADCEV is an ADC-approved medication for urothelial cancer patients with locally progressed or metastatic disease.

Antibody therapy is projected to expand in popularity in the future due to continual product approvals in both developing and established countries. Antibody treatment alternatives are exploding. In the forecast period, this may have an impact on the overall demand for antibody medication therapy. It can also lead to a plethora of replacements.

In addition, the adverse effects of antibody therapy can inhibit growth. Furthermore, genetic treatment is expensive. A combination of replica cells is also used in antibody therapy. It is possible to target and eliminate dangerous cells in the body. This one-of-a-kind procedure is pricey. As a result, the market for antibody therapy is shrinking.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Comparative View of Antibody Therapy Market

Antibody Therapy Market:

Attributes

Antibody Therapy Market

CAGR (2023 to 2033)

13.4%

Market Value (2033)

US$ 824 billion

Growth Factor

Globally, the prevalence of chronic and infectious diseases is increasing, along with the patients preferring protein over chemicals for therapy.

Opportunity

The biologics business is booming.

Antibody treatment is becoming more widely used, which is expected to open many horizons for the antibody therapy market.

Key Trends

Fast product approvals for COVID-19 treatment have aided the establishment of the antibody therapy sector during the epidemic.

Custom Antibody Market:

Attributes

Custom Antibody Market

CAGR (2023 to 2033)

10.4%

Market Value (2033)

US$ 1.3 billion

Growth Factor

A growth in research effort, particularly in the life sciences industry, as well as increased industry-academia partnership

Opportunity

The rising need for protein therapies and personalized medicine, as well as the discovery of newly designed proteins, are projected to create new opportunities.

Key Trends

Concerns over the quality of catalogue antibodies, as well as the growing antibody therapeutic pipeline, are projected to propel the market ahead.

Research Antibodies & Reagents Market:

Attributes

Research Antibodies & Reagents Market

CAGR (2023 to 2033)

6.5%

Market Value (2033)

US$ 23.15 billion

Growth Factor

Proteomics and genomics research is booming, and high-quality antibodies are in high demand for research repeatability.

Opportunity

Because of the region's diverse healthcare markets, the Asia Pacific region is likely to offer substantial growth prospects to market players in the coming years.

Key Trends

In the life sciences industry, research and development activity and spending are expanding, which provides a high growing opportunity for the market.

Antibody Therapy Market Country-wise Insights

Region

Absolute Market Growth

United States

US$ 207 billion

United Kingdom

US$ 23.9 billion

China

US$ 41.3 billion

Japan

US$ 32.5 billion

South Korea

US$ 18.4 billion

Which Region leads the Market in terms of Market Share and CAGR?

Huge Healthcare Budget along with Rising Number of Cancer Patients in the United States gains traction for the Market

United States Market CAGR (2023 to 2033)

13.1%

United States Market Absolute Doller Growth (US$ Million/Billion)

US$ 207.0 billion

The market is anticipated to continue to be dominated by the United States. Demand for antibody therapy is likely to be high, resulting in high growth. Furthermore, the region's advanced healthcare infrastructure and high healthcare spending are likely to boost the regional market growth.

Due to key players' increased investment in innovative antibody treatment development, the United States antibody therapy market flourished at a higher CAGR of 17.8% during the previous forecast period. As a result of the rising need for targeted medications in the region, clinical studies have increased, contributing to the market's overall growth. Though, the regional market now flourishes at a CAGR of 13.1% between 2023 and 2033, while it is likely to reach a value of US$ 291.9 billion by 2033.

What makes China a Leading Antibody Therapy Market?

Countries like China and India are Building their Advanced Healthcare Systems for the Huge Population

Region

Attributes

Chinese Market CAGR (2023 to 2033)

12.7%

Chinese Market Absolute Doller Growth (US$ Million/Billion)

US$ 41.3 billion

China with its leading cell-based science, along with the higher biological experiments, is expected to flourish at a steady CAGR of 12.7% between 2023 and 2033. The regional market is anticipated to reach a value of US$ 59.1 billion by 2033. Many patients are drawn to the therapy by low-cost treatments. In addition, the high prevalence of cancer fuels a massive demand for monoclonal antibody therapy. Antibody treatment is in high demand in this area.

The growth of an aging population increases chronic illness rates. This ultimately creates a positive impact on the antibody therapy market.

Category-wise Insights

Segment

Top Antibody

Top Sub-segment

Monoclonal Antibodies

CAGR (2017 to 2022)

18%

CAGR (2023 to 2033)

13.2%

Segment

Top End-User

Top Sub-segment

Hospitals

CAGR (2017 to 2022)

17.8%

CAGR (2023 to 2033)

12.6%

A lower degree of cross-reaction, homogeneity, and high specificity puts the segment on top

Monoclonal antibodies and antibody-drug conjugates are the two antibodies used in antibody therapy. Oncology, autoimmune diseases, infectious illnesses, and other diseases comprise the monoclonal antibodies industry.

Due to the increasing use of monoclonal antibodies (mAbs) to treat different diseases, such as cancer, infection, genetic diseases, and others, the monoclonal antibodies segment is predicted to grow at a 13.2% CAGR through 2023.

As biologic products, mAbs generate various immune-mediated reactions and responses, increasing the therapy's efficacy.

Higher Budget and Consumption are the driving factors for the Hospital Segment’s Growth

The antibody treatment market is divided into hospitals, specialty centers, and other end-users depending on end-use. The hospital segment thrives at the leading CAGR of 12.6% between 2023 and 2033. Due to guidelines, availability, and accessibility, increasing the number of people seeking treatment in hospitals is expected to boost the market growth. Other factors for this segment’s growth are advanced therapy, quick access to advanced care, post-treatment monitoring, presence of competent personnel all in one location

Competition Scenario

The fresh entry of significant players, on the other hand, may enhance competition. In addition, significant strategies in the competitive environment include expansion, acquisitions, partnerships, mergers, and acquisitions. In the approaching years, this market invests heavily in research and development to strengthen its position in the antibody industry and help them expand into big players.

Recent Market Developments

  • In January 2022, TEZSPIRE (tezepelumab-ekko) was approved and made available by Amgen and AstraZeneca to treat severe asthma. The FDA's approval of this medicine allows the corporation to expand its product line and generate significant income.
  • In November 2020, Regeneron received an Emergency Use Authorization (EUA) from the US Food and Drug Administration for its COVID-19 antibody combination casirivimab and imdevimab. This approval has boosted its revenue generation and helped it gain considerable market share.

Major Contributors of the Antibody Therapy Market

  • Bristol-Myers Squibb,
  • GlaxoSmithKline plc,
  • Takeda Pharmaceuticals,
  • Eli Lilly and Company,
  • Merck & Co, Inc.,
  • Seagen, Johnson & Johnson,
  • Novartis AG,
  • Regeneron Pharmaceuticals,
  • F. Hoffmann-La Roche Ltd.,
  • Merck & Co, IncSeagen

Key Segments

By Type:

  • Monoclonal Antibodies
    • Oncology, Autoimmune Disease
    • Infectious Disease
    • Other
  • Antibody Drug Conjugates

By End User:

  • Hospitals
  • Specialty Centers
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific (APAC)
  • Middle East & Africa (MEA)

Frequently Asked Questions

The antibody therapy market held a value of US$ 206.73 billion in 2022.

The market is estimated to hold a value of US$ 235.0 billion in 2023.

The antibody therapy market is anticipated to hold a share of US$ 824 billion by 2033.

The antibody therapy market flourished at 18.2% CAGR in the last four years, from 2017 to 2022.

The antibody therapy market is expected to register a CAGR of 13.4% by 2033.

Monoclonal is expected to dominate the antibody type category with a CAGR of 13.2% between 2023 and 2033.

The hospital segment is anticipated to top the end-user tally with a CAGR of 12.6% during the forecast period.

Table of Content

1. Executive Summary | Antibody Therapy Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Monoclonal Antibodies

            5.3.1.1. Oncology, Autoimmune Disease

            5.3.1.2. Infectious Disease

            5.3.1.3. Other

        5.3.2. Antibody Drug Conjugates

    5.4. Y-o-Y Growth Trend Analysis By Type, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Speciality Centers

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Type

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Type

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Type

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Type

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By End User

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. India

            11.2.1.4. Thailand

            11.2.1.5. Singapore

            11.2.1.6. Australia

            11.2.1.7. Rest of Asia Pacific

        11.2.2. By Type

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By End User

    11.4. Key Takeaways

12. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of Middle East and Africa

        12.2.2. By Type

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By End User

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. USA

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Type

            13.1.2.2. By End User

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Type

            13.2.2.2. By End User

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Type

            13.3.2.2. By End User

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Type

            13.4.2.2. By End User

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Type

            13.5.2.2. By End User

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Type

            13.6.2.2. By End User

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Type

            13.7.2.2. By End User

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Type

            13.8.2.2. By End User

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Type

            13.9.2.2. By End User

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Type

            13.10.2.2. By End User

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Type

            13.11.2.2. By End User

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Type

            13.12.2.2. By End User

    13.13. Thailand

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Type

            13.13.2.2. By End User

    13.14. Singapore

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Type

            13.14.2.2. By End User

    13.15. Australia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Type

            13.15.2.2. By End User

    13.16. GCC Countries

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Type

            13.16.2.2. By End User

    13.17. South Africa

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Type

            13.17.2.2. By End User

    13.18. Israel

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Type

            13.18.2.2. By End User

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Type

        14.3.3. By End User

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. F. Hoffmann-La Roche Ltd

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. AbbVie Inc

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Amgen Inc

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Bristol-Myers Squibb Company

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Johnson & Johnson Services, Inc

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Seagen

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Merck & Co. Inc

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Regeneron Pharmaceuticals Inc

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Novartis AG

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. AstraZeneca

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology
Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Type, 2017 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Type, 2017 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Type, 2017 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Type, 2017 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Type, 2017 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2017 to 2033

Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 17: Middle East and Africa Market Value (US$ Million) Forecast by Type, 2017 to 2033

Table 18: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2017 to 2033
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Type, 2017 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Type, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Type, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Type, 2017 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Type, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Type, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Type, 2017 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Type, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Type, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Type, 2017 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Europe Market Attractiveness by Type, 2023 to 2033

Figure 59: Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Type, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Type, 2017 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Type, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by End User, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: Middle East and Africa Market Value (US$ Million) by Type, 2023 to 2033

Figure 77: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 80: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: Middle East and Africa Market Value (US$ Million) Analysis by Type, 2017 to 2033

Figure 83: Middle East and Africa Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 84: Middle East and Africa Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 85: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2017 to 2033

Figure 86: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: Middle East and Africa Market Attractiveness by Type, 2023 to 2033

Figure 89: Middle East and Africa Market Attractiveness by End User, 2023 to 2033

Figure 90: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Antibody Purification Service Market

Published : July 2020

Healthcare

Cancer Antigens Market

Published : October 2019

Google translate

Antibody Therapy Market